Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02618616
Recruitment Status : Completed
First Posted : December 1, 2015
Results First Posted : July 20, 2021
Last Update Posted : July 20, 2021
Sponsor:
Information provided by (Responsible Party):
Ziarco Pharma Ltd

Brief Summary:
This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a PASI score of at least 10. Following run-in, subjects were randomized and received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: ZPL-3893787 Drug: Placebo Phase 2

Detailed Description:
This was a randomized, double blind, placebo controlled, parallel group study in 129 subjects with moderate to severe psoriasis with a Psoriasis Area and Severity Index (PASI) score of at least 10 and an Investigator's Global Assessment (IGA) of 3 (0-4 scale). Following run-in subjects received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks. Subjects attended the clinic at Baseline (Day 0) when they were reviewed and confirmed they met inclusion/exclusion criteria. Subjects were then randomized and received either oral 30 mg ZPL-3893787 once daily or placebo once daily for 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 129 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787- 18 (30 mg) Administered for 12 Weeks in Adult Subjects With Moderate to Severe Plaque Psoriasis
Actual Study Start Date : January 11, 2016
Actual Primary Completion Date : December 22, 2016
Actual Study Completion Date : December 22, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: ZPL-389
Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.
Drug: ZPL-3893787
Other Name: ZPL389

Placebo Comparator: Placebo
Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
Drug: Placebo



Primary Outcome Measures :
  1. Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 [ Time Frame: From baseline to week 12 ]
    The PASI is an assessment routinely used for evaluating and grading the severity of psoriatic lesions and their response to therapy. PASI divides the body into 4 regions: the head, trunk, upper extremities (arms) and lower extremities (legs). Each of these areas is assessed separately for erythema, in duration and scaling; these symptoms are scored on a 5-point scale from 0-4, where 0 = no symptoms and 4 =very marked. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents a reduction of at least 75% from baseline in the PASI score.


Secondary Outcome Measures :
  1. PASI-50 and PASI-75 Responders at Week 12 [ Time Frame: From baseline to week 12 ]
    PASI-75 and PASI-50 are defined as a 75% and 50% reduction, respectively, from baseline in PASI score at Week 12.

  2. Improvement in Investigator Global Assessment (IGA) at Week 12 [ Time Frame: From baseline to week 12 ]
    An overall assessment of the severity of psoriasis was made, by the investigator, using the IGA at each visit. IGA scores take values on a 5-point scale from 0-4, where 0 = clear to 4 = severe disease. Responder is defined as a score of clear or almost clear, or a reduction of ≥2 levels. Success is defined as a score of clear or almost clear. Subjects with discontinued and missing data categories at Week 12 were considered non-responders.

  3. Change From Baseline in the Numerical Rating Scale (NRS) for Pruritus (Worst Itch) at Week 12 [ Time Frame: From baseline to week 12 ]
    The pruritus NRS is an assessment tool used to assess the subject's worst itch as a result of psoriasis in the last 12 hours. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.

  4. Patient Global Impression of Change (PGIC) a Week 12 [ Time Frame: From baseline to week 12 ]

    At the end of treatment (Week 12) or early termination visit, the subject was asked to rate their degree of improvement (or worsening) of their psoriasis compared to before the start of treatment with study drug, using a 7-point scale, standardized PGIC.

    Since the start of the study (dosing), my overall status is:

    1. Very much improved
    2. Much improved
    3. Minimally improved
    4. No change
    5. Minimally worse
    6. Much worse
    7. Very much worse

  5. Change From Baseline in Body Surface Area (BSA) and Percentage Change From Baseline at Week 12 [ Time Frame: From baseline to week 12 ]
    Assessment of the percentage of a subject's BSA affected by psoriasis was made by best estimates of the investigator at each visit. Hand-size measurement was considered to be the "best estimate" to measure the BSA by the investigators.

  6. Change From Baseline in the Daytime and Night Time NRS for Pruritus (Worst Itch) at Week 12 [ Time Frame: From baseline to week 12 ]
    The subjects completed the NRS each morning on (or soon after) rising and evening prior to retiring to bed. They were asked the following question: On a scale of 0 (no itching) to 10 (itching as bad as you can imagine), please rate the worst itching that you felt over the last 12 hours.

  7. Change From Baseline in the NRS for Sleep Disturbance at Week 12 [ Time Frame: From baseline to week 12 ]
    In the morning subjects were asked the following question to determine the level of sleep disturbance due to itching: On a scale of 0 (no sleep disturbance) to 10 (awake all night), please rate how much your sleep was disturbed by itch last night.

  8. Change From Baseline in Total, Daytime and Night Time Duration of Itching at Week 12 [ Time Frame: From baseline to week 12 ]
    Subjects were asked the following question to determine their duration of itching: Over the last 12 hours approximately how many hours, if any, did you itch?

  9. Number of Participants for Each Verbal Rating Scale (VRS) Score for Pruritus at Week 12 [ Time Frame: From baseline to week 12 ]
    Subjects were asked to rate their itch over the last 12 hours using a list of adjectives describing different levels of symptom intensity: Over the last 12 hours how would you rate your itch? No itch; Mild; Moderate and Severe; Pruritus was evaluated by the subject, using the eDiary, twice daily for 1 week prior to the start of study treatment (run-in period) and during treatment (baseline to Day 84).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A documented history of moderate to severe plaque psoriasis for at least 6 months prior to screening.
  • Male or female, aged ≥18 years.
  • Psoriasis Area and Severity Index (PASI) ≥10 at both Screening and Day 0.
  • An Investigator's Global Assessment (IGA) score ≥ 3 at both Screening and Day 0.
  • Psoriasis affecting ≥10% body surface area (BSA) at Screening and Day 0.

Exclusion Criteria:

  • Current diagnosis of Pustular, Guttate, Erythrodermic, exfoliative or only nail psoriasis or a diagnosis of inverse psoriasis without having plaque psoriasis.
  • Concurrent skin disease (e.g. acne) of such severity in the study area that it could interfere with the study evaluation or presence of skin comorbidities that may interfere with study assessments.
  • Active skin infections (e.g. impetigo, abscesses) or any other clinically apparent infections.
  • Biologic treatments for psoriasis (e.g. Enbrel, Humira, Stelara, Cosentyx) within 3 months of the start of the Run-In.
  • Phototherapy (e.g. UVA, UVB, PUVA) within 4 weeks of the start of the Run-In.
  • Oral calcineurin inhibitors and immunosuppressants (e.g. cyclosporine, azathioprine, methotrexate) within 4 weeks of the start of the Run-In.
  • Systemic corticosteroids within 4 weeks of the start of the Run-In.
  • Oral antihistamines and leukotriene inhibitors and tricyclic antidepressants within 1 week of the start of the Run-In.
  • Topical steroids (any potency), topical calcineurin inhibitors (tacrolimus, pimecrolimus), salicylic acid and urea containing treatments and coaltar preparations, topical and oral retinoids and vitamin D derivatives, within 1 week of the start of the Run-In.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02618616


Locations
Layout table for location information
Belgium
Belgium Study Centre
Brussels, Belgium, 1000
Belgium Study Centre
Brussels, Belgium, 1090
Belgium Study Centre
Brussels, Belgium, 1200
Belgium Study Centre
Gent, Belgium, 9000
Belgium Study Centre
Leuven, Belgium, 3000
Belgium Study Centre
Liège, Belgium, 4000
Germany
German Study Centre
Berlin, Germany, 10117
German Study Centre
Goch, Germany, 47574
German Study Centre
Hamburg, Germany, 20354
German Study Centre
Hanover, Germany, 30625
German Study Centre
Mainz, Germany, 55131
German Study Centre
Münster, Germany, 48149
Poland
Polish Study Centre
Bialystok, Poland, 15-430
Polish Study Centre
Gdańsk, Poland, 80-405
Polish Study Centre
Lodz, Poland, 90-153
Polish Study Centre
Lublin, Poland, 20-552
Polish Study Centre
Poznan, Poland, 60-214
Polish Study Centre
Tarnow, Poland, , 33-100
Polish Study Centre
Wrocław, Poland, 50-220
Polish Study Centre
Łódź, Poland, 90-553
United Kingdom
UK Study Centre
Blackpool, United Kingdom, FY2 0JH
UK Study Centre
Bridgetown, United Kingdom, WS110BN
UK Study Centre
Leeds, United Kingdom, WS110BN
UK Study Centre
Manchester, United Kingdom, M13 9NQ
Sponsors and Collaborators
Ziarco Pharma Ltd
Investigators
Layout table for investigator information
Study Director: Study Director Novartis
Layout table for additonal information
Responsible Party: Ziarco Pharma Ltd
ClinicalTrials.gov Identifier: NCT02618616    
Other Study ID Numbers: ZPL389/102
First Posted: December 1, 2015    Key Record Dates
Results First Posted: July 20, 2021
Last Update Posted: July 20, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases